CoChat

Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion

Open access
Bowers, Jacob S., Nelson, Michelle H., Majchrzak, Kinga, Bailey, Stefanie R., Rohrer, Baerbel, Kaiser, Andrew D.M., Atkinson, Carl, Gattinoni, Luca, Paulos, Chrystal M. · 2017 · JCI Insight
Cited by 67

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Adoptive immunotherapy for solid tumors relies on infusing large numbers of T cells to mediate successful antitumor responses in patients. While long-term rapid-expansion protocols (REPs) produce sufficient numbers of CD8 + T cells for treatment, they also cause decline in the cell’s therapeutic fitness. In contrast, we discovered that IL-17–producing CD4 + T cells (Th17 cells) do not require REPs to expand 5,000-fold over 3 weeks. Also, unlike Th1 cells, Th17 cells do not exhibit hallmarks of senescence or apoptosis, retaining robust antitumor efficacy in vivo. Three-week-expanded Th17 cells eliminated melanoma as effectively as Th17 cells expanded for 1 week when infused in equal numbers into mice. However, treating mice with large recalcitrant tumors required the infusion of all cells generated after 2 or 3 weeks of expansion, while the cell yield obtained after 1-week expansion was insufficient. Long-term-expanded Th17 cells also protected mice from tumor rechallenge including lung metastasis. Importantly, 2-week-expanded human chimeric antigen receptor–positive (CAR + ) Th17 cells also retained their ability to regress human mesothelioma, while CAR + Th1 cells did not. Our results indicate that tumor-reactive Th17 cells are an effective cell therapy for cancer, remaining uncompromised when expanded for a long duration owing to their resistance to senescence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.90772

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 67

Metadata

Authors
Bowers, J. S., Nelson, M. H., Majchrzak, K., Bailey, S. R., Rohrer, B., Kaiser, A. D. M., Atkinson, C., Gattinoni, L., & Paulos, C. M.
Venue
JCI Insight
Published
2017-03-09
Volume
2
Issue
5
Pages
e90772-e90772
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2592127452
Cited by
67
References
8
FWCI
3.45
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. https://app.cochat.ai/papers/10.1172/jci.insight.90772
The paper
Bowers, J. S., Nelson, M. H., Majchrzak, K., Bailey, S. R., Rohrer, B., Kaiser, A. D. M., Atkinson, C., Gattinoni, L., & Paulos, C. M. (2017). Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight. https://doi.org/10.1172/jci.insight.90772

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.